Larimar Therapeutics (LRMR) President John Harlow Receives Award

What Happened
John B. Harlow Jr., President and COO of Larimar Therapeutics (LRMR), received equity awards totaling 850,000 units on September 29, 2026. The filing shows a grant of 50,000 restricted stock units (RSUs) and 800,000 derivative awards, all granted at $0.00 per share (total reported value $0). These were awards/grants (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-09-29; Form 4 filed 2026-10-01 (timely filing).
• Awards: 50,000 RSUs (each RSU is a contingent right to one share) and 800,000 derivative units granted at $0.00.
• Vesting: Footnote indicates a vesting schedule (25% on Sept 29, 2027, then remaining 75% in equal monthly installments over the next 36 months), subject to continued service — applies to the derivative award per the filing.
• Shares owned after the transaction: not disclosed in the provided data.
• Transaction type: Award/Grant (A) — not an immediate purchase or sale; no cash changed hands at grant.

Context

• These awards are compensation grants subject to vesting and settlement terms; they do not represent immediate market purchases or sales. For retail investors, awards signal management compensation alignment but are not the same as an insider buying shares with personal funds.